Latent Labs develops AI foundation models and generative tools to design proteins from scratch and optimize molecular features like affinity and stability. The platform is intended to let biotechnology and pharmaceutical partners computationally generate new therapeutic molecules such as antibodies and enzymes, accelerating discovery and improving success rates. The company emerged from stealth and says partners can leverage its models to unlock challenging targets and shorten drug development timelines. Latent Labs experimentally validates its AI platform in lab facilities and operates from offices in London and San Francisco. The team is led by founder and CEO Dr. Simon Kohl, a former DeepMind researcher who co-led DeepMind’s protein design efforts on AlphaFold2, and has attracted talent from DeepMind, Microsoft, Google, Stability AI, Exscientia, Mammoth Bio, Altos Labs and Zymergen. The company announced a $50M financing to accelerate progress and partnerships.

Total raised

$40M

Funding rounds

1

Latest round

Series A

Latest activity

Feb 2025